Facing increased sexually transmitted infection incidence in HIV preexposure prophylaxis cohorts: what are the underlying determinants and what can be done?

Purpose of review The combined incidence of chlamydia, gonorrhoea and syphilis in MSM PrEP (preexposure prophylaxis) cohorts now frequently exceeds 100 per 100 person years. The efficacy of antiretroviral PrEP in reducing HIV transmission has led to efforts to find similar biomedical ways reduce sexually transmitted infection (STI) incidence. We review the recent evidence for these and other strategies. Recent findings Doxycycline PrEP/postexposure prophylaxis has been shown to reduce the incidence of syphilis and chlamydia but not gonorrhoea. A meningococcal vaccine has been found to result in a lower incidence of gonorrhoea. Novel insights into the role of the pharynx in the transmission of gonorrhoea have led to clinical trials of oral antiseptics to reduce the spread of gonorrhoea. Intensified STI screening has been introduced in a number of clinics. Serious concerns have however been raised about the emergence of resistance to each of these strategies. This is particularly true for doxycycline PrEP which is not advocated by any guidelines we reviewed. Summary Randomized controlled trials are urgently required to ascertain the benefits and risks of interventions to reduce STIs in MSM PrEP cohorts.
Source: Current Opinion in Infectious Diseases - Category: Infectious Diseases Tags: STD: Edited by Joseph A. Duncan Source Type: research

Related Links:

Background Streptococcus pneumonia is a significant cause of morbidity and mortality in adults who are immunocompromised and of advanced age. It is the standard of care to vaccinate all high-risk adults (18-64 years) and adults 65 years and older with 2 pneumococcal vaccines. However, pneumococcal immunization rates remain below the HealthyPeople2020 target goal of 90% nationally and locally.
Source: Journal of the American Medical Directors Association - Category: Health Management Authors: Source Type: research
The drug maker said that in March it would begin two more clinical trials of remdesivir, an experimental antiviral drug, in more nations outside China.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Vaccination and Immunization Clinical Trials Gilead Sciences Inc Remdesivir your-feed-healthcare Source Type: news
Experimental Models of Tauopathy - From Mechanisms to Therapies. Adv Exp Med Biol. 2019;1184:381-391 Authors: Götz JJ, Götz J Abstract Animal models have been instrumental in reproducing key aspects of human tauopathy. In pursuing these efforts, the mouse continues to have a prominent role. In this chapter, we focus on models that overexpress wild-type or mutant forms of tau, the latter being based on mutations found in familial cases of frontotemporal dementia. We review some of these models in more detail and discuss what they have revealed about the underlying pathomechanisms, as well...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Rejecting vaccinations causes significant economic and mortality costs.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
BOSTON (CBS) – The Centers for Disease control has cautioned that, based on current patterns, coronavirus is likely to become a global pandemic. With no approved vaccine or medication to treat it, that could ultimately result in overloaded healthcare systems. What is a pandemic? Simply put, a pandemic is a global, widespread outbreak of a new illness. Because it is new, people don’t have the ability to fight it and can be easily infected. The last pandemic to widely affect the United States was H1N1 flu in 2009. The worst pandemic in history was the Spanish flu outbreak in 1918 which killed 50 million people wo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated Local Coronavirus Source Type: news
As the coronavirus spreads, Novavax Inc. is moving forward to find a defense against it. The Gaithersburg company, which a month ago set out to develop a vaccine for the COVID-19 coronavirus, is now evaluating candidates in animal models — a critical step toward testing in humans. Now Novavax (NASDAQ: NVAX) hopes to receive Food and Drug Administration approval to start human clinic al trials by the end of this spring, it said Wednesday, a fast timeline relative to the yearslong research and development…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Authors: Bergeron HC, Tripp RA Abstract Introduction. Respiratory syncytial virus (RSV) causes lower respiratory tract infections and can lead to morbidity and mortality in the infant, elderly and immunocompromised. There is no vaccine and therapeutic interventions are limited. RSV disease research has yielded the development of several prophylactic and therapeutic treatments. Several promising candidates are currently under investigation.Areas covered. Small and large molecule approaches to RSV treatment were examined and categorized by their mechanism of action using data from PubMed, clinicaltrials.gov, and from...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
According to a Feb. 21Morbidity and Mortality Weekly Report from the CDC, the current influenza vaccine has been 45% effective overall against 2019-2020 seasonal influenza A and B viruses.
Source: AAFP News - Category: Primary Care Source Type: news
Publication date: April 2020Source: Fish &Shellfish Immunology, Volume 99Author(s): Mostafa Halimi, Mojtaba Alishahi, Mohammad Reza Abbaspour, Masoud Ghorbanpoor, Mohammad Reza Tabandeh
Source: Fish and Shellfish Immunology - Category: Biology Source Type: research
Okay, I'm not an epidemiologist or a virologist. But I do know something about those subjects, I'm a public health professor, and I am an expert in clinical communication and risk communication. So I'm going to offer some observations that I hope will help people keep this public health scare in proper perspective and maybe be of practical use.There are two important parameters we need to understand the risk caused by any communicable disease. I'm going to broadly say transmissibility, and the probability that exposure will lead to serious disease.We often see transmissibility represented as a single number, called R0 or &...
Source: Stayin' Alive - Category: American Health Source Type: blogs
More News: Chlamydia | Clinical Trials | Doxycycline | Gonorrhoea | Infectious Diseases | Men | Meningitis | Meningitis Vaccine | STDs | Syphilis | Vaccines